References
- Ciprandi G, Buscaglia S, Cerqueti PM, et al. Drug treatment of allergic conjunctivitis. A review of the evidence. Drugs 1992;43:154-76
- Abelson MB, Smith L, Chapin M. Ocular allergic disease: mechanisms, disease subtypes, treatment. Ocul Surf 2003;1:127-49
- Akdis CA, Blaser K. Histamine in the immune regulation of allergic inflammation. J Allergy Clin Immunol 2003;112:15-22
- Rondon C, Fernandez J, Canto G, et al. Local allergic rhinitis: concept, clinical manifestations, and diagnostic approach. J Investig Allergol Clin Immunol 2010;20:364-71
- Udell IJ, Abelson MB. Animal and human ocular surface response to a topical nonimmune mast-cell degranulating agent (compound 48/80). Am J Ophthalmol 1981;91:226-30
- Smith JA, Mansfield LE, de Shazo RD, et al. An evaluation of the pharmacologic inhibition of the immediate and late cutaneous reaction to allergen. J Allergy Clin Immunol 1980;65:118-21
- Abelson MB, Udell IJ. H2-receptors in the human ocular surface. Arch Ophthalmol 1981;99:302-4
- Physicians’ Desk Reference for Ophthalmic Medications, 32nd edn. Montville, NJ: Thomson PDR, 2004
- Guest JF, Davie AM, Ruiz FJ, et al. Switching asthma patients to a once-daily inhaled steroid improves compliance and reduces healthcare costs. Prim Care Respir J 2005;14:88-98
- Lockey RF, Widlitz MD, Mitchell DQ, et al. Comparative study of cetirizine and terfenadine versus placebo in the symptomatic management of seasonal allergic rhinitis. Ann Allergy Asthma Immunol 1996;76:448-54
- Hughes JL, Lackie PM, Wilson SJ, et al. Reduced structural proteins in the conjunctival epithelium in allergic eye disease. Allergy 2006;61:1268-74
- Ono SJ, Abelson MB. Allergic conjunctivitis: update on pathophysiology and prospects for future treatment. J Allergy Clin Immunol 2005;115:118-22
- Wan H, Winton HL, Soeller C, et al. The transmembrane protein occludin of epithelial tight junctions is a functional target for serine peptidases from faecal pellets of Dermatophagoides pteronyssinus. Clin Exp Allergy 2001;31:279-94
- Megens AAHP, Awouters J, Vermeire J. In vivo antiallergic activity of R87314 and R89674 in the Ascaris allergy test in dogs: a comparison with noberastine, loratadine, and terfenadine. Janssen Research Foundation PreClinical Research Report N109428/1 (February 1995). 1995
- Ono SJ, Lane K. Comparison of effects of alcaftadine and olopatadine on conjunctival epithelium and eosinophil recruitment in a murine model of allergic conjunctivitis. Drug Design Dev Ther 2011;5:1-8
- Abelson MB, Chambers WA, Smith LM. Conjunctival allergen challenge. A clinical approach to studying allergic conjunctivitis. Arch Ophthalmol 1990;108:84-8
- Abelson MB, Gomes P, Crampton HJ, et al. Efficacy and tolerability of ophthalmic epinastine assessed using the conjunctival antigen challenge model in patients with a history of allergic conjunctivitis. Clin Ther 2004;26:35-47
- Abelson MB, Turner D. A randomized, double-blind, parallel-group comparison of olopatadine 0.1% ophthalmic solution versus placebo for controlling the signs and symptoms of seasonal allergic conjunctivitis and rhinoconjunctivitis. Clin Ther 2003;25:931-47
- Torkildsen GL, Williams JI, Abelson MB, et al. Bepotastine besilate ophthalmic solution for the relief of nonocular symptoms provoked by conjunctival allergen challenge. Ann Allergy Asthma Immunol 2010;105:57-64
- Greiner JV, Edwards-Swanson K, Ingerman A. Evaluation of alcaftadine 0.25% ophthalmic solution in acute allergic conjunctivitis at 15 minutes and 16 hours after instillation versus placebo and olopatadine 0.1%. Clin Ophthalmol 2011;4:1-7
- LASTACAFT (alcaftadine ophthalmic solution) 0.25% [prescribing information]. Jacksonville, Fl: Vistakon Pharmaceuticals, LLC, 2010
- Abelson MB, Loeffler O. Conjunctival allergen challenge: models in the investigation of ocular allergy. Curr Allergy Asthma Rep 2003;3:363-8
- Torkildsen G, Gomes P, Williams J, et al. Evaluation of bepotastine besilate ophthalmic solution 1.0% in the conjunctival allergen challenge model of allergic conjunctivitis. 112th Annual Meeting of the American Academy of Ophthalmology. Atlanta, GA, 2008
- Abelson MB, Gomes PJ, Pasquine T, et al. Efficacy of olopatadine ophthalmic solution 0.2% in reducing signs and symptoms of allergic conjunctivitis. Allergy Asthma Proc 2007;28:427-33